Metabolic PET Imaging as an early biomarker of cardiac toxicity following treatment with the tyrosine kinase inhibitor sunitinib

被引：0
|
作者：
Byrne, Annette T. [1 ]
机构：
[1] Royal Coll Surgeons Ireland, Dept Physiol & Med Phys, Lab Tumour Biol & Mol Imaging, Dublin 2, Ireland
来源：
ANGIOGENESIS | 2014年 / 17卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
O-38
引用
收藏
页码：726 / 727
页数：2
相关论文
共 50 条
  • [41] Dosimetry of 18F-Labeled Tyrosine Kinase Inhibitor SKI-249380, a Dasatinib-Tracer for PET Imaging
    Mark P. S. Dunphy
    Pat Zanzonico
    Darren Veach
    Romel Somwar
    Nagavarakishore Pillarsetty
    Jason Lewis
    Steven Larson
    Molecular Imaging and Biology, 2012, 14 : 25 - 31
  • [42] Sunitinib Malate, a Receptor Tyrosine Kinase Inhibitor, Is Effective in the Treatment of Restrictive Heart Failure due to Heart Metastases from Renal Cell Carcinoma
    Szmit, Sebastian
    Zagrodzka, Magdalena
    Kurzyna, Marcin
    Opolski, Grzegorz
    Szczylik, Cezary
    CARDIOLOGY, 2009, 114 (01) : 67 - 71
  • [43] PROTEOMIC ANALYSIS OF MALIGNANT GLIOMA TISSUE FOLLOWING TREATMENT WITH THE RECEPTOR TYROSINE KINASE INHIBITOR ZD6474
    Wibom, C.
    Sandstrom, M.
    Henriksson, R.
    Johansson, M.
    Antti, H.
    Bergenheim, T.
    NEURO-ONCOLOGY, 2008, 10 (06) : 1109 - 1109
  • [44] Salvage surgery following tyrosine kinase inhibitor treatment for advanced non-small cell lung cancer
    Kobayashi, Masao
    Funaki, Soichiro
    Nagata, Hideki
    Furukawa, Mitsugi
    Morii, Eiichi
    Shintani, Yasushi
    SURGICAL CASE REPORTS, 2024, 10 (01):
  • [45] Improved overall survival following tyrosine kinase inhibitor (TKI) treatment in NSCLC-are we making progress?
    Fenchel, Klaus
    Dale, Stephen P.
    Dempke, Wolfram C. M.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2016, 5 (04) : 373 - 376
  • [46] the Charlson Comorbidity Index Predicts Survival Following Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia Patients
    Imataki, Osamu
    Uchida, Shumpei
    Oku, Maki
    Yokokura, Shigeyuki
    Uemura, Makiko
    Kadowaki, Norimitsu
    BLOOD, 2015, 126 (23)
  • [47] A Pilot Study of FLT-PET as an Early Imaging Biomarker in the Trimodality Treatment of Patients With Thoracic Malignancies
    Jain, A. K.
    Lameka, K. A.
    Yan, S. X.
    Zhao, B.
    Divgi, C.
    Leung, D. K.
    Cheng, S. K.
    Chao, K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S669 - S669
  • [48] Inhibition of erbB1/2 by small molecule tyrosine kinase inhibitors, but not trastuzumab, affects metabolic pathways: implications to cardiac toxicity
    Bacus, S. S.
    Trusk, P.
    Lyass, L.
    Hill, J. E.
    Spector, N. L.
    EJC SUPPLEMENTS, 2006, 4 (12): : 170 - 170
  • [49] Tyrosine kinase inhibitor sunitinib therapy is effective in the treatment of bone metastasis from cancer of unknown primary: Identification of clinical and immunohistochemical biomarkers predicting survival
    Ma, Yifei
    Zhou, Wang
    He, Shaohui
    Xu, Wei
    Xiao, Jianru
    INTERNATIONAL JOURNAL OF CANCER, 2016, 139 (06) : 1423 - 1430
  • [50] Two methods for labeling tyrosine kinase inhibitor sorafenib with carbon-11 to obtain a PET tracer for personalized cancer treatment
    Poot, A.
    Van der Wildt, B.
    Stigter-van Walsum, M.
    Schuit, R.
    Van Dongen, G.
    Windhorst, A.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S28 - S28
12345